These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1608475)

  • 21. Iron metabolism and iron substitution during erythropoietin therapy.
    Sunder-Plassmann G; Hörl WH
    Clin Investig; 1994; 72(6 Suppl):S11-5. PubMed ID: 7950165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of anemia of chronic renal failure.
    Singh NP; Anuradha S; Chandrashekhar ; Agarwal SK
    J Assoc Physicians India; 1999 Feb; 47(2):216-23. PubMed ID: 10999096
    [No Abstract]   [Full Text] [Related]  

  • 23. How to save money for erythropoietin therapy by changing from 'roller coaster' to continuous iron supplementation.
    Canavese C; Grill A; De Costanzi E; Martina G; Buglione E; Valente D; David O; Saitta M; Maddalena E; Barbieri S; Fop F; Salomone M; Piccoli G
    Nephron; 1999; 81(3):362-3. PubMed ID: 10050100
    [No Abstract]   [Full Text] [Related]  

  • 24. [The need for blood transfusions in intermittent hemodialysis].
    Hoier-Madsen K; Krogsgaard AR; Pedersen K
    Ugeskr Laeger; 1973 Oct; 135(40):2143-51. PubMed ID: 4789477
    [No Abstract]   [Full Text] [Related]  

  • 25. rhEPO treatment of anemia in uremic patients.
    Bommer J; Barth HP; Schwöbel B
    Contrib Nephrol; 1990; 87():59-67. PubMed ID: 2093542
    [No Abstract]   [Full Text] [Related]  

  • 26. [Correction of anemia in hemodialysis, effect of intravenous iron without erythropoietin].
    Alvo M; Elgueta L; Aragón H; Cotera A
    Rev Med Chil; 2002 Aug; 130(8):865-8. PubMed ID: 12360794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A trial of oral iron in dialysis patients.
    Strickland ID; Chaput de Saintonge DM; Boulton FE; Brain AJ; Goodwin FJ; Marsh FP; Zychova Z
    Clin Nephrol; 1974; 2(1):13-7. PubMed ID: 4595978
    [No Abstract]   [Full Text] [Related]  

  • 28. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
    Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
    Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iron management during recombinant human erythropoietin therapy.
    Van Wyck DB
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the evening i.v. administration of erythropoietin in haemodialyzed patients.
    Buemi M; Allegra A; Laganà A; Aloisi C; Privitera M; Morabito N; Frisina N
    Riv Eur Sci Med Farmacol; 1993; 15(5-6):195-7. PubMed ID: 7761669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of maternal iron stores in pregnancy. Panel discussion.
    McGanity WJ; Kitay D; Rayburn WF
    J Reprod Med; 1987 Jun; 32(6 Suppl):488-96. PubMed ID: 3612642
    [No Abstract]   [Full Text] [Related]  

  • 32. Iron deficiency in Latin America. Causes and prevention.
    Layrisse M
    Int J Vitam Nutr Res Suppl; 1985; 27():105-16. PubMed ID: 3926686
    [No Abstract]   [Full Text] [Related]  

  • 33. Serum erythropoietin titers in the anemia of chronic renal failure and other hematological states.
    Urabe A; Saito T; Fukamachi H; Kubota M; Takaku F
    Int J Cell Cloning; 1987 May; 5(3):202-8. PubMed ID: 3598244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of fractional or massive doses of exogenous ESF in uremic patients].
    Lamperi S; Fiorio P
    Boll Soc Ital Biol Sper; 1976 Dec; 52(23):1978-84. PubMed ID: 1027470
    [No Abstract]   [Full Text] [Related]  

  • 35. Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia.
    Milman N
    Clin Nephrol; 1982 Feb; 17(2):77-81. PubMed ID: 6802544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Iron metabolism pre and post the erythropoietin era].
    Jacobs C
    Nephrol Ther; 2006 Nov; 2 Suppl 5():S313-20. PubMed ID: 17373276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment with high-dose intravenous iron increases mortality and hospitalization in hemodialysis. The basic idea is more important than the style].
    Fernández-Gallego J
    Nefrologia; 2005; 25(3):340. PubMed ID: 16053019
    [No Abstract]   [Full Text] [Related]  

  • 38. [Iron supplementation during erythropoietin therapy in patients on hemodialysis].
    Svára F; Sulková S; Kvasnićka J; Polakovic V
    Vnitr Lek; 1996 Dec; 42(12):849-52. PubMed ID: 9072885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of hypochromic anemia. Comparative study of a "slow-release" and a conventional iron preparation].
    Larsen MS
    Nord Med; 1971 Mar; 85(9):267-72. PubMed ID: 5554713
    [No Abstract]   [Full Text] [Related]  

  • 40. The use of iron in patients on chronic dialysis: mistake and misconceptions.
    Sakiewicz P; Paganini E
    J Nephrol; 1998; 11(1):5-15. PubMed ID: 9561479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.